Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $261.25 USD
Change Today +1.70 / 0.65%
Volume 2.0M
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

pharmacyclics inc (PCYC) Key Developments

Pharmacyclics Inc. Announces European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat Waldenstrom's Macroglobulinemia

Pharmacyclics Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending a change to the terms of the marketing authorization for IMBRUVICA® (ibrutinib) in the European Union to indicate the treatment of adult patients with Waldenström's macroglobulinemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.1 WM is a rare, slow growing form of blood cancer.2 IMBRUVICA is also the first and only FDA-approved treatment for WM in the United States.3 The CHMP recommendation follows the January 2015U.S. Food and Drug Administration (FDA) full approval of IMBRUVICA to treat all lines of patients with WM. IMBRUVICA is jointly developed and commercialized in the United States by Pharmacyclics and Janssen Biotech Inc. In Europe, Janssen-Cilag International NV (Janssen) holds the marketing authorization and its affiliates market IMBRUVICA in EMEA (Europe, Middle East, Africa), as well as the rest of the world. IMBRUVICA is already approved in Europe to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) and adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. WM currently affects approximately 23,000 patients in the G7 countries (United States, France, Germany, Italy, Japan and the United Kingdom).3 The CHMP recommendation was based on a multi-center, Phase II study that evaluated the efficacy and tolerability of IMBRUVICA in 63 patients with previously treated WM. Initial data from the study submitted for review in the EU showed an overall response rate (ORR) of 87.3% after a median duration of treatment of 11.7 months.

Pharmacyclics Inc. Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2015

Pharmacyclics Inc. announced unaudited consolidated earnings results for first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $205,772,000, income from operations of $3,781,000, income before income taxes of $4,233,000, net income of $4,147,000 or $0.05 per diluted share, non-GAAP net income of $33,970,000 or $0.43 per diluted share compared to the total revenue of $119,377,000, income from operations of $18,225,000, income before income taxes of $18,263,000, net income of $18,275,000 or $0.23 per diluted share, non-GAAP net income of $31,261,000 or $0.4 per diluted share for the same quarter a year ago.

Pharmacyclics Inc.(NasdaqGS:PCYC) dropped from NASDAQ Biotechnology Index

Pharmacyclics Inc. will be removed from NASDAQ Biotechnology Index.

Pharmacyclics, Inc. Announces Initiation of PCYC-1135-CA, Multi-Center Study

Pharmacyclics Inc. announced the initiation of PCYC-1135-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational, anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca. The Phase Ib/II study will examine the safety, tolerability and effectiveness of this investigational combination in individuals with relapsed or refractory (R/R) non-small cell lung cancer (NSCLC), breast cancer, and pancreatic cancer. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech Inc. The Phase Ib portion of the study will primarily seek to determine the safety, tolerability, and appropriate dose of ibrutinib when combined with MEDI4736 to treat individuals with these cancers. The Phase II portion of the study will be conducted in three distinct cohorts to determine the safety and effectiveness of the treatment combination in individuals with R/R NSCLC, breast and pancreatic cancers. The clinical study will aim to enroll approximately 160 subjects at approximately 20 sites in the U.S.

Pharmacyclics Inc. Announces New Pre-Clinical and Clinical Data for ibrutinib (IMBRUVICA)

Pharmacyclics Inc. announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA®) will be highlighted at the 2015 American Association for Cancer Research (AACR) Annual Meeting to be held April 18 " 22, 2015, in Philadelphia, PA. Several company-sponsored and investigator-initiated abstracts have been accepted for presentation as oral and poster sessions highlighting data in solid tumor and blood cancers. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech Inc. Long-term treatment with single-agent ibrutinib 420 mg leads to durable responses including complete responses in CLL (Abstract CT132) Clinical Trials Minisymposium. IMBRUVICA (ibrutinib) is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK).1 BTK is a key signaling molecule in the B-cell receptor signaling complex that plays an important role in the survival and spread of malignant B cells.1,2 IMBRUVICA blocks signals that tell malignant B cells to multiply and spread uncontrollably.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCYC:US $261.25 USD +1.70

PCYC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.133.00 CHF -1.40
Alexion Pharmaceuticals Inc $171.94 USD +3.37
BioMarin Pharmaceutical Inc $127.19 USD +0.31
Genmab A/S kr577.50 DKK +2.50
Vertex Pharmaceuticals Inc $125.08 USD +0.03
View Industry Companies
 

Industry Analysis

PCYC

Industry Average

Valuation PCYC Industry Range
Price/Earnings 100.0x
Price/Sales 24.4x
Price/Book 22.5x
Price/Cash Flow 277.0x
TEV/Sales 23.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.